NCT01444690Unknown2 期
Dimiracetam in Painful Neuropathies Affecting AIDS Patients. A Double-blind, Placebo-controlled, Parallel-group, Randomised, Multi-centre Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- Neurotune AG
- 入组人数
- 244
- 试验地点
- 1
- 主要终点
- Pain intensity measured on 100 mm VAS
研究概览
简要总结
The purpose of this study is to assess the efficacy and tolerability of orally administered dimiracetam for 10 weeks to AIDS patients under treatment with antiretroviral agents presenting a disease and /or treatment related neuropathic pain.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •male and female patients aged 18-75 years inclusive;
- •females of child-bearing potential only if agreeing prior to screening to use a medically accepted method of contraception, i.e., oral or injectable hormonal contraceptive with a second method of birth control, medically prescribed intrauterine device (IUD), or double barrier method (condom in combination with spermicidal). Females, who are not currently sexually active, only if agreeing and consenting to use one of the above-mentioned methods in case they become sexually active while participating in the study;
- •females of not child-bearing potential only if permanently sterilised or if in post-menopausal status, only if they have been in this status for at least 2 years; females of not child-bearing potential are exempted from the requirement for use of contraception;
- •HIV-positive patients treated with ARTs;
- •CD4+ cell count > 200/μL at the screening;
- •patients affected by current neuropathic pain likely to be ART treatment related. The diagnosis shall be made by a physician and based on history, clinical and/or laboratory findings in accordance with the taxonomy of the diagnostic criteria documented in the International Association for the Study of Pain (IASP) Classification of Chronic Pain;
- •naïve neuropathic patients or non-responders (residual pain ≥40 mm on the VAS) to standard neuropathy treatments. Drugs for neuropathic pain (NP) must be stopped at screening visit;
- •pain intensity ≥40 mm on the VAS at screening;
- •pain intensity ≥40 mm on the VAS as the mean of the values collected on the last 4 days prior to the start of treatment (baseline VAS);
- •life expectancy of at least 6 months;
- •ability to comprehend the full nature and purpose of the study, including possible risks and side effects;
- •ability to co-operate with the Investigator or designee and to comply with the requirements of the entire study
排除标准
- •pregnant or lactating females;
- •presence of active AIDS-defining opportunistic infections (with the exception of tuberculosis) or malignant neoplasia requiring treatment at study entry or Kaposi's sarcoma or another malignant neoplasia likely to require chemotherapy;
- •any clinically significant underlying disease, according to the Investigator's clinical judgment;
- •history of psychosis (e.g. schizophrenia or psychotic depression) or major depression (requiring treatment);
- •any current DSM-IV Axis I diagnosis including dementia, depression, psychosis, anxiety disorders, mental retardation;
- •participation in the evaluation of any investigational drug within 3 months prior to screening (6 months if for treatment of neuropathic pain)
- •treatment with neurostimulating devices such as spinal cord stimulation (SCS), acupuncture, homeopathic remedies for pain or any kind of surgical treatment or blockade for the pain in the 4 weeks prior to screening;
- •treatment with any drug for neuropathic pain (NP) after the screening visit;
- •requirement of more than 2 transfusions / month to achieve haemoglobin level > 8 g/dL;
- •history of alcohol abuse (no more than 4 drinks in a day and 14 drinks in a week for men or 3 drinks per day and 7 drinks in a week for women as defined according to both NIAAA and USDA dietary guidelines) or drug abuse during the last 3 mo prior to screening;
- •Less than 1 VAS assessment per day for each of the last 4 days.
- •history of allergic response to neuropathic treatments or history of anaphylaxis or allergic reactions to drugs in general;
- •any abnormality that the Investigator deems to be clinically relevant, either on medical history, physical examination, ECG or in diagnostic laboratory test;
- •subjects likely to be non-compliant or uncooperative during the study according to the Investigator or designee's judgement
研究组 & 干预措施
Pseudo-placebo
Placebo Comparator
Dimiracetam 25 mg capsules
干预措施: Dimiracetam 25 mg (Drug)
Active
Experimental
Dimiracetam 400 mg capsules
干预措施: Dimiracetam (Drug)
结局指标
主要结局
Pain intensity measured on 100 mm VAS
时间窗: 71 days
Change from baseline in pain intensity as measured on VAS
Pain intensity as measured with Total Symptom Score (TSS)
时间窗: 71 days
Change from baseline as measured with TSS
次要结局
- Adverse events(78 days)
- Number needed to treat(71 days)
- CD4+ cell count(78 days)
- HIV viral load(78 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Study of DTC in Patients With AIDS and AIDS Related ComplexHIV InfectionsNCT00002069Merieux Institute
已完成
2 期
Niclosamide for Mild to Moderate COVID-19COVID-19NCT04399356Tufts Medical Center73
终止
2 期
The Effect of Lacosamide in Peripheral Neuropathic PainNeuropathic PainNeuropathy, PainfulNeuropathy, DiabeticNeuropathyPeripheral NeuropathyNCT03777956Danish Pain Research Center63
已完成
1 期
Diethylhomospermine (DEHSPM) for Refractory AIDS-Related DiarrheaDiarrheaHIV InfectionsNCT00002121VA Medical Center-Gainesville
Unknown
1 期
Treatment of Advanced AIDS Patients With Dextrin SulfateHIV InfectionsNCT00004987Steinhart Medical Associates